Description
BCR-ABL (chronic
myelogenpus/acute lymphoblastic leukemia assy-by pcr
Sample Type:2Whole Blood
Tests Included:
BCR-ABL fusion gene detection via Polymerase Chain Reaction (PCR).
Sample Required:
Blood sample.
Test Time:
Results are typically available within a few days.
Test Range Values:
The results are reported as a ratio or percentage of the BCR-ABL gene to a reference gene. A higher ratio or percentage indicates a greater number of leukemia cells.
What is the test?
This test detects the BCR-ABL fusion gene, which is a genetic abnormality found in chronic myelogenous leukemia (CML) and some cases of acute lymphoblastic leukemia (ALL). PCR amplifies and detects this gene’s presence in the blood.
Test Procedure:
A blood sample is collected and analyzed in the laboratory using PCR techniques to identify the presence and quantity of the BCR-ABL fusion gene.
When to take the test:
The BCR-ABL test is typically ordered to diagnose, monitor, and evaluate the effectiveness of treatment in individuals with CML or specific cases of ALL.
Who should take the test:
Patients with suspected CML or ALL, individuals diagnosed with these conditions to monitor their response to treatment, or those with symptoms like unexplained fatigue, abnormal bleeding, or enlarged spleen may require this test.
Precautions for exceptional cases (pregnancy, etc.):
There are no known risks or special precautions related to pregnancy for the BCR-ABL test. However, pregnant individuals should inform their healthcare provider before undergoing any medical test or procedure.
Frequently Asked Questions (FAQs) for BCR-ABL Test:
Q1: What does a positive BCR-ABL test mean?
A: A positive result indicates the presence of the BCR-ABL fusion gene, confirming the diagnosis of chronic myelogenous leukemia (CML) or certain cases of acute lymphoblastic leukemia (ALL).
Q2: How is the BCR-ABL test used to monitor treatment progress?
A: The test helps track response to therapy by quantifying the amount of BCR-ABL gene present. A decreasing level over time often indicates a positive response to treatment.
Q3: Are there any risks associated with the BCR-ABL test?
A: Generally, the test is safe, but as with any blood draw, there might be minimal risks like bruising or infection at the puncture site.
Q4: Can the BCR-ABL test detect relapse in leukemia patients?
A: Yes, an increasing level of BCR-ABL gene after achieving remission may suggest a relapse, prompting further evaluation and treatment adjustments.
Q5: How often should the BCR-ABL test be done for monitoring purposes?
A: The frequency depends on the individual’s treatment plan and response. Initially, it might be more frequent, and then the intervals may widen based on treatment efficacy.
*Please note that specific testing protocols and guidelines may vary based on the latest recommendations from health authorities and regulatory agencies. It is essential to consult healthcare professionals and follow local testing guidelines for accurate and appropriate testing.
